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Abstract
Background and Aim: The interaction between hepatitis C virus (HCV) and innate antiviral defense systems in primary
human hepatocytes is not well understood. The objective of this study is to examine how primary human hepatocytes
response to HCV infection.
Methods: An infectious HCV isolate JFH1 was used to infect isolated primary human hepatocytes. HCV RNA or NS5A protein
in the cells was detected by real-time PCR or immunofluorescence staining respectively. Apoptosis was examined with flow
cytometry. Mechanisms of HCV-induced IFN-b expression and apoptosis were determined.
Results: Primary human hepatocytes were susceptible to JFH1 virus and released infectious virus. IFN-a inhibited viral RNA
replication in the cells. IFN-b and interferon-stimulated genes were induced in the cells during acute infection. HCV infection
induced apoptosis of primary human hepatocytes through the TRAIL-mediated pathway. Silencing RIG-I expression in
primary human hepatocytes inhibited IFN-b and TRAIL expression and blocked apoptosis of the cells, which facilitated viral
RNA replication in the cells. Moreover, HCV NS34A protein inhibited viral induced IFN-b expression in primary human
hepatocytes.
Conclusion: Innate host response is intact in HCV-infected primary human hepatocytes. RIG-I plays a key role in the
induction of IFN and TRAIL by viruses and apoptosis of primary human hepatocytes via activation of the TRAIL-mediated
pathway. HCV NS34A protein appears to be capable of disrupting the innate antiviral host responses in primary human
hepatocytes. Our study provides a novel mechanism by which primary human hepatocytes respond to natural HCV
infection.
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Introduction
Hepatitis C virus (HCV) infection is a rapidly increasing public
health problem, with an estimated 170 million infected patients
worldwide [1]. It causes significant liver disease ranging from
chronic hepatitis to cirrhosis and even hepatocellular carcinoma
[2]. Unfortunately, there is no vaccine available for HCV and only
a subset of HCV patients response to interferon alpha (IFN-a) and
Ribavirin treatment. In contrast to most other viral infection, the
hallmark of HCV infection is that the majority patients (up to
80%) will develop chronic infection after viral exposure [1,2].
However, around 25% to 50% of HCV infected patients resolve
acute HCV infection without treatment [1], indicating that innate
and/or adaptive immune responses are capable of controlling the
outcome of HCV infection. Processes that regulate innate
intracellular antiviral responses may therefore serve as pivotal
points of control, potentially limiting host permissiveness for HCV
replication.
Virus-induced production of type I IFNs and the subsequent
expression of IFN-stimulated genes (ISGs) are central to these
antiviral defenses [3]. Production of type I IFN by virus-infected
cells is the central event in their antiviral immune response. In
mammalian cells, IFN gene transcription is induced through
distinct signaling pathways by viral infection or by double-strand
RNA (dsRNA) treatment. IFN triggers the innate cellular antiviral
response, which functions to limit viral replication.
Previous HCV infection studies have involved infected patients
[4,5] and chimpanzees [6,7]. The recent development of infectious
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27552HCV clone (JFH1) provides a very powerful tool for the analysis of
host-virus interactions [8–10]. However, antiviral responses have
been studied in human hepatic-derived cell lines especially Huh7
and its derivative Huh7.5 cells which differ from the primary
human hepatocytes (PHH) in their antiviral signaling pathways in
response to viral infection [11,12].
The current study was to explore the innate immune response of
PHH to infectious HCV infection. Our study shows that infectious
HCV can induce innate immune responses in PHH via induction
of IFN and triggering apoptosis of infected cells. Retinoic acid
inducible gene-I (RIG-I) plays a key role in HCV-induced IFN
expression and regulates the induction of tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) and apoptosis in PHH
by viral infection. Moreover, HCV NS34A protein appears to be




All patients signed consent forms to acknowledge participation
in this study approved by the review board of the Hunan
Provincial Tumor Hospital, Changsha, China. All procedures
followed were in accordance with the ethical commission of
Hunan Provincial Tumor Hospital, Changsha, China. Primary
human hepatocytes were obtained from healthy peritumoral liver
resection specimens from 13 non-HBV, non-HCV and non-HIV
infected patients undergoing partial hepatectomy for primary
hepatocellular carcinoma or secondary metastatic lesions due to
other cancers.
Cell culture, reagent
Primary human hepatocytes were isolated from healthy
peritumoral liver tissues and cultured as described previously
[13]. TRAIL or RIG-I shRNA lentiviral particles targeted human
TRAIL or RIG-I was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Huh7.5 cells were kindly provided by Dr.
Charles Rice (Rockefeller University, New York, NY).
Transduction of primary human hepatocytes
5610
5 of PHHs were plated in each well of 6-well plate and
incubated overnight with TRAIL, RIG-I or control shRNA
lentiviral particles at multiplicity of infection (MOI) of 1 with
5 mg/mL polybrene (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Culture medium was changed and cells were maintained
for 48 hours prior to HCV infection.
Transfection of primary human hepatocytes
To obtain the high efficient transfection of primary human
hepatocytes, we performed the transfection experiments using
Effectene transfection reagent (Qiagen, Valencia, CA). In briefly,
plasmid pTOPO or pTOPO-NS34A was first mixed with
Enhancer and a buffer that provides optimal salt conditions for
efficient DNA condensation at room temperature for 5 minutes.
Effectene Reagent was then added and the mixture was incubated
for 10 minutes to allow Effectene–DNA complexes to form. The
complexes were mixed with culture medium and added directly to
the cells. The cells were incubated until harvested.
Real-time PCR assays
Total cellular RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. The
primers targeted HCV, IFN-b, TRAIL, DR4, DR5 and G1P3
have been reported previously [14] and real-time PCR were
performed as described previously [14]. Results were analyzed
using 2.0 software (Applied Biosystem, Foster City, CA).
Immunofluorescence
Primary human hepatocytes were seeded on glass coverslips pre-
coated with rat tail collagen type I and fixed with ice-cold acetone
for 10 minutes at 220uC. The cells were washed with PBS,
blocked with 1:50 goat serum for 30 minutes at room temperature
and then incubated for 1 hour with mouse monoclonal anti-NS5A
antibody generated at University of Florida (Gainesville, FL). The
cells were stained with FITC-labeled goat anti-mouse IgG for 45
minutes at room temperature. The coverslips were extensively
washed and the nuclei were counterstained with DAPI (Vector
Laboratories Inc, Burlingame, CA). Fluorescent images were
obtained using fluorescent microscope (Olympus, Japan).
Flow cytometry analysis
The Annexin V-FITC apoptosis detection kit was purchased
from BD Pharmingen (San Diego, CA). The procedure has been
reported previously [14]. Samples were analyzed on a FACS
Caliber Cytometer (BD Pharmingen, San Diego, CA). The data
were analyzed with CellQuest software.
Statistical Analysis
Student t-test was applied to determine statistical significance. P
values of ,0.05 were considered statistically significant.
Results
HCV infects PHH and induces IFN-b and ISGs in the cells
JFH1 virus, a genotype 2 virus, was cloned from a Japanese
patient with fulminate hepatitis C [8–10]. The infection of
hepatoma cell Huh7.5 by JFH1 provides an opportunity to
explore the interaction between human hepatocytes and HCV. To
get enough infectious HCV, we transfected viral RNA transcribed
from the full-length HCV genotype 2a JFH1 or a replication-
incompetent mutant (JFH1/GND) plasmid into Huh7.5 cells.
Transfected cells were passaged every 3–5 days. Cell supernatant
was harvested at day 18 after transfection and then used to infect
naı ¨ve Huh7.5 cells. The immunofluorescence staining data
showed that around 70–80% of the cells were positive for HCV
NS5A protein at day 5 after viral infection (Figure 1A), while no
NS5A-positive stained Huh7.5 cells inoculated with superna-
tant from JFH1/GND RNA-transfected cells were observed
(Figure 1B). These results suggest that Huh7.5 cells transfected
with JFH1 RNA are able to produce infectious viral particles.
Huh7.5 cells are poorly differentiated hepatoma cells. More-
over, they lack a functional RIG-I signaling pathway because of
mutant RIG-I (T55I) in the cells and do not appear to produce
detectable type I IFN when JFH1 virus is used for viral infection
[14–16]. Thus, Huh7.5 cells may not mount an intact innate
antiviral system. To better understand the interaction between the
virus and its natural host cells, we isolated PHH from the human
liver tissues and tried to replicate the JFH1 virus in the cells. To
test whether JFH1 viruses infect PHH, we inoculated primary
human hepatocytes Hu441 with the supernatant collected from
JFH1 or JFH1/GND RNA-transfected Huh7.5 respectively. The
cells grew on glass coverslips and were stained by immunofluo-
rescence for HCV protein assay. As shown in Figure 1C, HCV
NS5A-positive signal was only detected in Hu441 inoculated with
supernatant from JFH1 RNA-transfected Huh7.5 cells, while cells
incubated with supernatant from JFH1/GND RNA-transfected
Huh7.5 did not show positively for HCV NS5A (Figure 1D). We
inoculated other nine primary human hepatocytes preparations
Response of Human Hepatocyte to HCV Infection
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27552Figure 1. HCV infects primary human hepatocytes and induces IFN-b and ISGs in the cells. (A) Filtered supernatant from JFH1 RNA-
transfected Huh7.5 cells was inoculated with naive Huh7.5 cells. Cells were immunostained with mouse monoclonal anti-NS5A antibody at day 5 after
inoculation. DAPI was used for nuclear counterstaining. (B) Filtered supernatant from JFH1/GND RNA-transfected Huh7.5 cells was inoculated with
naive Huh7.5 cells. Cells were stained at day 5 after inoculation as described in part A. (C) Filtered supernatant from JFH1 RNA-transfected Huh7.5
cells was inoculated with primary human hepatocytes Hu441. Cells were stained at day 5 after inoculation as described in part A. (D) Filtered
supernatant from JFH1/GND RNA-transfected Huh7.5 cells was inoculated with primary human hepatocytes Hu441. At day 5 after inoculation, cells
were stained as described in part A. (E/F) Naı ¨ve Huh7.5 cells were incubated for 3 days with filtered, conditioned media from Hu441 cells preinfection
with supernatant from JFH1 RNA-transfected Huh7.5 cells (E) or Hu441 pre-inoculated with supernatant from JFH1/GND RNA-transfected Huh7.5 (F)
and immunostained for NS5A expression. (G) Viral RNA kinetics determined by real-time PCR analysis in ten different PHH preparations and Huh7.5
cells infected by JFH1 virus. The HCV RNA in PHH was determined by quantitative real-time PCR analysis. The viral replication is represented by HCV
genome equivalence (GE)/mg total RNA of HCV-infected PHH. The ten PHH preparations are primary human hepatocytes Hu401 (from 31-year-old
female with liver mass in left lobe), Hu414 (from 65-year-old male with liver mass), Hu441 (from 65-year-old male with metastasis of a colic tumor),
Hu583 (from 40-year-old female with liver adenoma), Hu0586 (from 69-year-old female with metastatic endometrial uterine cancer), Hu606 (from 44-
year-old female with hemangioma), Hu749 (from 79-year-old female with metastatic ovarian), Hu750 (from 39-year-old female with hemangioma),
Hu786 (from 70-year-old male with hepatocellular carcinoma), Hu831 (from 41-year-old male with hepatocellular carcinoma). (H) IFN inhibited HCV
RNA replication in PHH in a dose-dependent manner. The data represent the relative RNA levels after 2 days of IFN-a treatment. These results are
representative of observations made with PHH cultures from three different donors (PHHs are Hu750, Hu786 and Hu787 from 48-year-old female with
metastasis of a colic tumor). (I) Anti-CD81 antibody blocked HCV infection in PHH. Primary human hepatocytes were pretreated with anti-CD81
antibody for 2 hours before viral inoculation. Viral RNA was analyzed by real-time PCR at day 3 post-infection. Data are means from three
independent assays. These results are representative of observations made with PHH cultures from three different donors (PHH are Hu750, Hu786
and Hu787). (J/K) Kinetics of IFN-b and G1P3 in viral infected PHH. Three different PHH preparations (Hu583, Hu586 and Hu786) from three donors
were infected with JFH1 virus at MOI of 0.1. Cells were harvested for total RNA extraction at different time points. The kinetics of induction of IFN-b (J)
and G1P3 (K) was analyzed by real-time PCR assay. The data were normalized with internal control glyceraldehyde-3- phosphate dehydrogenase
(GAPDH) and represent the means of 3 different PHHs from 3 different donors.
doi:10.1371/journal.pone.0027552.g001
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Huh7.5 respectively and observed the similar result as shown in
Hu441. In order to determine if the JFH1 virus-infected PHHs
release infectious virus, we inoculated naı ¨ve Huh7.5 cells with the
filtered supernatant from viral infected Hu441. Huh7.5 cells grew
on the glass coverslips and were stained by immunofluorescence
for HCV NS5A protein assay. As shown in Figure 1E, Huh7.5
cells inoculation with the supernatant from JFH1-infected PHH
were positive for HCV NS5A protein, while cells inoculated with
supernatant from JFH1/GND-pretreated PHHs did not show
positively for HCV NS5A (Figure 1F). These results clearly show
that JFH1-infected PHH can release infectious virus.
To get the HCV infection kinetics in PHHs, we inoculated ten
different primary human hepatocyte preparations with JFH1
viruses at MOI of 0.1. Total cellular RNA was purified from the
PHH at different time point. Viral RNA replication was detected
with real-time PCR analysis as reported previously [14]. Viral
RNA could be easily detected in ten different PHH preparations
infected by JFH1 virus at different time points although it was
much lower in PHH than that in Huh7.5 cells (Figure 1G). To tell
the difference between the inputted viral RNA and newly
synthesized viral RNA, we treated the virus-infected PHH with
IFN-a or anti-CD81 antibody respectively. As shown in Figure 1H,
viral RNA replication in PHH was suppressed by IFN-a in a dose-
dependent manner. When PHH were treated with anti-CD81
antibody before viral inoculation, viral infection efficiency was
markedly decreased in a dose-dependent manner (Figure 1I). Our
data strongly indicate that primary human hepatocytes are
susceptible to JFH1 virus and release infectious virus.
Production of type I IFN by virus-infected cells is the central
event in their antiviral immune response. To determine whether
HCV can induce IFN expression in PHHs, we infected three
different PHH preparations with JFH1 virus and monitored IFN-b
expression at different time points using real-time PCR assay. The
expression of IFN-b in PHH was detected as early as 6 hours and
reached a peak at 72 hours postinfection (Figure 1J). The protein
levels in the supernatant from HCV-infected PHH were too low to
be detected. The induction of IFN-b by JFH1 in Huh7.5 cells was
barely detectable in similar condition.
IFN triggers the innate cellular antiviral response to limit viral
replication and functions through activation of interferon
stimulated genes (ISGs). Our previous study showed that G1P3
has been implicated as IFN-inducible gene [3]. G1P3 plays a
functional role in IFN-induced antiviral pathway. To confirm the
IFN-induced antiviral pathway is functional in PHH, we tested the
expression of G1P3 in viral infected PHH. As shown in Figure 1K,
the expression of G1P3 could be detected as early as 6 hours and
reached a peak at 96 hours after infection and started to decrease
gradually in PHH. The induction of G1P3 could not be detected
in viral infected Huh7.5 cell. We tested 1-8U, another ISG, in
HCV-infected PHH and observed the same phenomenon. These
data strongly suggest that JFH1 virus can induce the type I IFN
and ISGs in PHHs.
HCV infection induces apoptosis of PHH through TRAIL-
mediated pathway
Some of the primary human hepatocytes infected with JFH1
virus died, although Huh7.5 cells did not show apparent cell death
after similar viral infection. To test whether cell death involves
apoptosis in HCV-infected PHH, we infected three different PHH
preparations with JFH1 virus and performed Annexin V staining
with flow cytometry. As shown in Figure 2A, higher level of
Annexin V was detected in JFH1-infected PHH compared with
the control. Huh7.5 cells did not show apparent Annexin V
staining after viral infection. These data indicate that JFH1 causes
apoptosis in PHH. To further test that apoptosis of PHH is directly
related to viral infection, we performed a series of experiments.
CD81 is a critical component of HCV receptor [17], so we
blocked viral infection using the antibody against human CD81
(Figure 1I). As shown in Figure 2B, blocking viral infection with
anti-CD81 antibody markedly reduced apoptosis of viral infected
PHH. IFN-a was used to inhibit viral replication in PPH
(Figure 1H). Inhibition of HCV replication also prevented PHH
from apoptosis (Figure 2B). Moreover, apoptosis was in time-
dependent manner, corresponding to the viral replication in PHH
(Figure 2C). These data clearly indicate that HCV infection is
responsible for the apoptosis of PHH.
The activation of TRAIL death pathway has been shown in
other viral infection [14,18]. To explore the mechanisms by which
HCV induces apoptosis of PHH, we examined the expression of
TRAIL in virus-infected PHH using real-time PCR analysis. As
shown in Figure 2D, TRAIL was detected as early as 24 hours and
peaked at day 4 after infection in PHH, while the expression of
TRAIL in Huh7.5 cells could not be detectable. The data indicate
that the expression kinetics of TRAIL was correlated with the cell
apoptosis (Figure 2C and 2D). It prompted us to hypothesize that
TRAIL death pathway may be involved in the apoptosis of PHH
with HCV infection because a similar pathway has been suggested
in other viral infection [18]. To test our hypothesis, we examined
the expression of TRAIL receptors, DR4 and DR5. As shown in
Figure 2D, DR4 and DR5 were both induced and peaked at day 4
after viral infection (Figure 2D). The induction of DR4 and DR5
in Huh7.5 cells was barely detectable under similar condition.
These data indicate that TRAIL signaling pathway is activated by
HCV infection, which may be responsible for apoptosis of PHH.
To address the causal relationship between HCV-induced
apoptosis and TRAIL activation, we performed a series of
experiments. TRAIL siRNA was delivered into PHH before the
cells were infected by JFH1. Apoptosis of the cells was examined
by flow cytometry analysis. The data showed that TRAIL-specific
siRNA efficiently knocked down its mRNA in HCV-infected PHH
(Figure 2E). When TRAIL siRNA was transfected into PHH
followed by viral infection, HCV-induced apoptosis was signifi-
cantly reduced in comparison with the control (Figure 2F). These
data strongly suggest that HCV induces apoptosis of PHH through
TRAIL-mediated pathway.
Silencing RIG-I expression in primary human hepatocytes
inhibits IFN-b expression and blocks apoptosis of PHH via
TRAIL-mediated pathway in response to HCV infection
It has been reported that RIG-I plays an important role in
dsRNA-induced innate antiviral responses [19,20]. To test if RIG-
I plays a role in IFN induction by HCV infection in PHH, we
performed siRNA knockdown experiments. We confirmed that
RIG-I siRNA could significantly knock down its messenger RNA
(Figure 3A). When RIG-I siRNA was delivered into PHH followed
by HCV infection, IFN-b was markedly reduced in comparison
with the control (Figure 3A). Moreover, knocking down RIG-I
inhibited TRAIL expression in HCV-infected PHHs and
significantly blocked apoptosis of the cells (Figure 3B and 3C).
Inhibition of IFN-b expression and blockage of HCV-induced
apoptosis caused by silencing RIG-I expression in PHH
contributed to the enhanced HCV RNA replication level and
elevated HCV protein level in comparison with the control
(Figure 3D and 3E). All the data support that RIG-I is responsible
for the induction of IFN-b and TRAIL and apoptosis of primary
human hepatocytes via TRAIL-mediated pathway in response to
HCV infection.
Response of Human Hepatocyte to HCV Infection
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27552Figure 2. HCV induces apoptosis of PHH through TRAIL-mediated pathway. (A) HCV induces apoptosis of PHHs. Three different PHHs
(Hu507, Hu606 and Hu831) from three donors were infected by JFH1 virus at MOI of 0.1. The cells were harvested at day 5 after infection and
subjected to Annexin V analysis determined by Flow cytometry. The data represent the means of 3 different PHHs from 3 different donors. (B)
Blocking viral entry by anti-CD81 antibody or suppression of HCV replication by IFN reduces apoptosis of PHHs. Three PHH (Hu507, Hu606 and
Hu831) were treated with 100IU/mL or anti-CD81 two hours before viral infection. The cells were harvested at day 5 post-infection for Annexin V
expression determined by Flow cytometry analysis. The data represent the means of 3 different PHHs from 3 different donors. (C) Kinetics of
apoptosis in HCV-infected PHHs. Three different PHHs (Hu507, Hu606 and Hu831) from three donors were infected by JFH1 virus at MOI of 0.1. The
cells were harvested every 24 hours and subjected to Annexin V analysis determined by Flow cytometry. The data represent the means of 3 different
PHHs from 3 different donors. (D) HCV induces the expression of TRAIL, DR4 and DR5 in PHHs. Three different PHHs were infected by JFH1 virus and
total RNA was purified from the cells at different time points. The expression of TRAIL, DR4 or DR5 was examined by real-time PCR analysis. The data
were normalized with GAPDH and represent the means of 3 different PHHs (Hu507, Hu606 and Hu831) from 3 different donors. (E) TRAIL-specific
siRNA knockdown HCV-induced TRAIL expression in PHH. TRAIL siRNA or control siRNA were delivered into PHH infected by HCV. The expression of
TRAIL was examined using real-time PCR. The data were normalized with internal control GAPDH and represented the means of 3 different PHHs
(Hu507, Hu606 and Hu831) from 3 different donors. The image showed the effectiveness of TRAIL-specific siRNA on knocking down TRAIL mRNA in
HCV-infected PHHs, as determined by RT-PCR analysis using TRAIL-specific primer. (F) TRAIL knockdown with TRAIL-specific siRNA reduces HCV-
induced apoptosis of PHHs. TRAIL siRNA or control siRNA was delivered into PHHs followed by HCV infection for 5 days. Apoptosis of PHHs was
examined using flow cytometry. The data represent the means of 3 different PHHs (Hu507, Hu606 and Hu831) from 3 different donors.
doi:10.1371/journal.pone.0027552.g002
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infection in primary human hepatocytes
Many reports indicate that HCV NS34A inhibits IFN-b
expression in hepatocytes [21–23]. However, all the studies were
performed in HCV replicon cell lines or hepatoma cell
transfection systems. To explore whether HCV NS34A interferes
with the antiviral responses and contributes to its immune evasion
strategy in PHH, we used primary human hepatocytes in our
study. Our data showed that HCV replication was very low in
primary human hepatocytes (Figure 1G). It may require abundant
HCV NS34A protein accumulation in the PHH to execute its
blockage of IFN-b induction signaling. To test our hypothesis, we
overexpressed HCV NS34A protein in primary human hepato-
cytes to examine its impact on the induction of IFN-b by viral
infection. Primary human hepatocytes were transfected with
plasmid pTOPO-NS34A followed by JFH1 virus infection and
the level of IFN-b was determined with real-time RT-PCR
analysis. As shown in Figure 4A, the cells overexpressing HCV
Figure 3. Silencing RIG-I expression in PHH inhibits the expression of IFN-b and reduces apoptosis of PHH in response to HCV
infection. (A) RIG-I knockdown with RIG-I-specific siRNA inhibits IFN-b expression in PHH. RIG-I siRNA or control siRNA was delivered into PHH. The
expression of IFN-b was examined using real-time PCR. The data were normalized with internal control GAPDH and represented the means of 3
different PHH (Hu507, Hu606 and Hu831) from 3 different donors. The image showed the effectiveness of RIG-I-specific siRNA on knocking down RIG-I
mRNA in viral infected PHHs, as determined by RT-PCR analysis using RIG-I-specific primer. (B) RIG-I regulates TRAIL expression in HCV-infected PHH.
PHHs were transfected with control siRNA or RIG-I-specific siRNA for 24 hours, followed by viral infection. The cells were harvested for total cellular
RNA extraction and the expression of TRAIL in the cells was examined using real-time RT-PCR. (C) RIG-I knockdown with RIG-I-specific siRNA reduces
HCV-induced apoptosis of PHH. RIG-I siRNA or control siRNA was delivered into PHH followed by HCV infection for 5 days. Apoptosis of PHH was
examined using flow cytometry. The data represent the means of 3 different PHHs (Hu507, Hu606 and Hu831) from 3 different donors. (D) Relative
HCV RNA level in PHH transfected with RIG-I siRNA. PHH were transfected with RIG-I or control siRNA, followed by viral infection for 72 hours. Total
RNA was isolated and HCV RNA was detected using real-time PCR. The data was normalized with GAPDH and represented the means of 3 different
PHHs (Hu507, Hu606 and Hu831) from 3 different donors. (E) Immunostaining of HCV NS5A protein in PHH with RIG-I downregulation. PHHs were
transfected with RIG-I or control siRNA, followed by viral infection for 72 hours. The cells were immunostained with mouse monoclonal anti-NS5A
antibody. DAPI was used for nuclear counterstaining.
doi:10.1371/journal.pone.0027552.g003
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expression of NS34A protein in PHH containing the plasmid
pTOPO-NS34A was confirmed (Figure 4B). To further examine if
HCV NS34A inhibit the induction of IFN-b by other virus, we
transfected primary human hepatocytes with plasmid pTOPO-
NS34A and then used Newcastle disease virus (NDV) to infect the
cells. Total cellular RNA was isolated and the level of IFN-b was
determined with real-time RT-PCR analysis. The data showed
that HCV NS34A indeed inhibited the induction of IFN-b by
NDV in PHHs (Figure 4C). All the results suggest that HCV
NS34A inhibits the induction of IFN-b by viral infection in PHH.
Discussion
Various hepatic cell models including hepatoma cell lines Huh7,
Huh7.5 and immortalized human hepatocyte were used to address
innate immune response to HCV. The transformed, rapidly
dividing and poor differentiated hepatoma cells differ from normal
primary human hepatocytes, raising doubts as to the in vivo
relevance of the widely used in vitro system. Because HCV
replication in vivo occurs mainly in highly differentiated, non-
dividing human hepatocytes, PHH closely mimic the natural
target cell of the virus and are the best model of choice for the
study HCV infection physiopathology and hepatocarcinogenesis in
vitro [24,25]. To explore the interaction between HCV and its
natural host cells, we used primary human hepatocytes in this
study. Although JFH1 virus was able to infect the majority of
Huh7.5 cells, only about 10% to 15% of primary human
hepatocytes were infected by the same virus based on our study.
In agreement with the study, one recent report showed that about
10% of hepatocytes in the liver tissue of hepatitis C patients were
infected by the virus [26]. A more recent study reported
production of infectious virus upon HCV inoculation of micro-
patterned co-cultures (MPCC) of PHH and supportive stroma in a
multiwell format, but only 1-5% of the cells were infected by the
virus, probably due to the microscale plate used [27]. It has been
demonstrated that Huh7.5 cell line contains an inactivating
mutation in RIG-I [16], an important component for interferon
response via virus-related dsRNA-sensing machinery and thus
lacks a functional RIG-I signaling pathway. JFH1 virus fails to
induce type I IFN and ISGs expression in this cell line [14,28,29].
However, the same viruses are able to induce the IFN-b and ISGs
expression in PHH and induction of IFN-b by viral infection in
PHH depends on RIG-I signaling pathway. The levels of viral
RNA were much lower in PHH than those in Huh7.5 cells. One of
the reasons may be related to the activation of innate antiviral
responses in PHH with HCV infection. The intact innate immune
system evidenced by induction of IFN-b and ISGs in PHH and
apoptosis of PHHs in response to HCV infection may contribute
to viral fluctuation and low viral replication efficiency in PHH,
which was demonstrated in the study.
Our data showed that cytotoxic effect of HCV infection in PHH
is through TRAIL-mediated apoptosis. It has been reported that
HCV infection can sensitize human hepatocytes to TRAIL-
induced apoptosis [30]. Another HCV-2a strain has been reported
to induce cellular apoptosis in immortalized human hepatocytes
[31]. TRAIL might be a target gene of IRF-3 [32]. IRF-3 is
related to TRAIL expression in viral infected hepatoma cell line
[14]. The present data showed that RIG-I regulates TRAIL
expression and is responsible for HCV-induced apoptosis of
primary human hepatocytes via activation of TRAIL-mediated
pathway. The mechanisms by which HCV induces the expression
of TRAIL need to be explored. HCV core protein has been
indicated in regulation of apoptosis [33]. It would be interesting to
determine the impact of core protein on DR4 and DR5
expression. Our current study is the first report about that RIG-
I is responsible for apoptosis of primary human hepatocytes via
activation of TRAIL-mediated pathway.
Our study demonstrated the mechanism by which infectious
HCV induces cytopathic and noncytopathic antiviral response in
PHH. Apoptosis of HCV-infected PHH is an efficient way to
eradicate viral infection. Production of type I IFN protects the
uninfected cells from viral infection. It is logical for the virus to
develop evasion mechanisms by which the virus minimizes its
cytolytic activity and inhibits IFN production in the host cells to
establish persistent infection in the presence of innate intracellular
antiviral response. Many studies have provided experimental
evidences to demonstrate how HCV inactivates host innate
antiviral response. It has been suggested that HCV NS34A
interferes with RIG-I signaling pathway and cleaves Cardif/IPS-
Figure 4. HCV NS34A inhibits IFN-b expression in viral-infected
PHH. (A) The plasmid pTOPO-NS34A or control plasmid pTOPO was
transfected into PHH, followed by HCV infection for 3 days. Total RNA
was isolated and IFN-b level was detected using real-time PCR analysis.
The expression level of IFN-b RNA was normalized with GAPDH. The
data represent the means of 2 different PHHs (Hu507 and Hu593) from
2 different donors. (B) Overexpression of HCV NS34A in PHH. pTOPO or
pTOPO-NS34A plasmid was transfected into PHHs respectively. Protein
was isolated from the cells at day 2 after transfection and used for
western blot analysis with anti- HCV NS34A antibody. (C) HCV NS34A
inhibits the induction of IFN-b by NDV. PHH were transfected by
plasmid pTOPO-NS34A or pTOPO, followed by NDV infection at MOI of
0.1. Total cellular RNA was isolated at 48 hours after infection and the
level of IFN-b was determined with real-time RT-PCR analysis. The level
of IFN-b RNA was normalized with GAPDH. The data represent the
means of 3 different PHHs (Hu441, Hu507 and Hu593) from 3 different
donors.
doi:10.1371/journal.pone.0027552.g004
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[34–38]. However, all these studies were performed through
experiments using HCV RNA replicon and hepatoma cell
transfection systems. The recent development of infectious JFH1
virus provides a very powerful tool for the analysis of host-virus
interactions [8–10]. However, antiviral responses have been
studied in human hepatic-derived cell lines especially Huh7 and
its derivative Huh7.5 cells which may differ from the primary
human hepatocytes in their antiviral signaling pathways. It is
essential to determine whether HCV NS34A interferes with the
IFN-b production in primary human hepatocytes during natural
viral infection. Our study demonstrated that HCV NS34A is
capable of inhibiting virus-induced IFN-b expression in PHH,
which facilitates persistent viral infection.
In conclusion, our study has clearly demonstrated that PHH
have intact innate host response evidenced by induction of IFN-b
and ISGs and apoptosis in the cells with HCV infection. RIG-I
plays a key role in the induction of IFN and TRAIL and apoptosis
of PHH via activation of TRAIL-mediated pathway in response to
natural HCV infection. HCV NS34A protein appears to be
capable of disrupting the innate antiviral host responses in PHH.
These findings reveal the mechanism by which primary human
hepatocytes respond to natural HCV infection. The in vitro system
for the replication of infectious JFH1 in primary human
hepatocytes should facilitate the molecular analysis of infectious
virus-host interactions.
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